pp32 reduction induces differentiation of TSU-Pr1 cells

被引:25
作者
Brody, JR [1 ]
Kadkol, SS [1 ]
Hauer, MC [1 ]
Rajaii, F [1 ]
Lee, J [1 ]
Pasternack, GR [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA
关键词
D O I
10.1016/S0002-9440(10)63117-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
pp32 (ANP32A) is a nuclear phosphoprotein expressed as a nomnutated form in self-renewing cell populations and neoplastic cells. Mechanistically, PP32 may regulate pathways important in the process of differentiation as part of separate complexes inhibiting histone acetylation and regulating immediate-early and cytokine mRNA stability. Prostatic adenocarcinomas express pp32 in a differentiation related manner-well-differentiated tumors express lower levels of PP32 than poorly differentiated tumors. In benign prostate, PP32 is expressed in basal cells but not in terminally differentiated glandular cells. Based on these observations, we hypothesized that reduction of pp32 expression might be an important differentiation signal. We used antisense pp32 and RNAi transfection to study the effects of reduced pp32 expression in the TSU-Pr1 carcinoma cell line. pp32 reduction induced Tsu-Pr1 cells to differentiate into neuronal-like cells with associated inhibition of growth. Reduction of pp32 and consequent differentiation were accompanied by a marked reduction in expression of SET, which complexes with PP32, by a marked change in acetylation status of histone 114, and by further differential expression of genes in differentiation pathways. Thus, reduction of PP32 in the undifferentiated TSU-Pr1 neoplastic cell line induces differentiation and thus may be an element of a differentiation control pathway in both normal and neoplastic cells.
引用
收藏
页码:273 / 283
页数:11
相关论文
共 32 条
  • [1] Tumor suppression and potentiation by manipulation of pp32 expression
    Bai, JN
    Brody, JR
    Kadkol, SHS
    Pasternack, GR
    [J]. ONCOGENE, 2001, 20 (17) : 2153 - 2160
  • [2] Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status
    Bonkhoff, H
    [J]. ANNALS OF ONCOLOGY, 2001, 12 : S141 - S144
  • [3] Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival
    Bostwick, DG
    Qian, JQ
    Pacelli, A
    Zincke, H
    Blute, M
    Bergstralh, EJ
    Slezak, JM
    Cheng, L
    [J]. JOURNAL OF UROLOGY, 2002, 168 (03) : 1204 - 1211
  • [4] Protein ligands to HuR modulate its interaction with target mRNAs in vivo
    Brennan, CM
    Gallouzi, IE
    Steitz, JA
    [J]. JOURNAL OF CELL BIOLOGY, 2000, 151 (01) : 1 - 13
  • [5] Identification of sequences required for inhibition of oncogene-mediated transformation by pp32
    Brody, JR
    Kadkol, SS
    Mahmoud, MA
    Rebel, JMJ
    Pasternack, GR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (29) : 20053 - 20055
  • [6] Butler LM, 2000, CANCER RES, V60, P5165
  • [7] Carlson SG, 1998, J AM SOC NEPHROL, V9, P1873
  • [8] CELL-PROLIFERATION IN PROSTATIC ADENOCARCINOMA - INVITRO MEASUREMENT BY 5-BROMODEOXYURIDINE INCORPORATION AND PROLIFERATING CELL NUCLEAR ANTIGEN EXPRESSION
    CARROLL, PR
    WALDMAN, FM
    ROSENAU, W
    COHEN, MB
    VAPNEK, JM
    FONG, P
    NARAYAN, P
    MAYALL, BH
    [J]. JOURNAL OF UROLOGY, 1993, 149 (02) : 403 - 407
  • [9] CARTER BS, 1990, CANCER RES, V50, P6830
  • [10] The oncoprotein Set/TAF-1β, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing
    Cervoni, N
    Detich, N
    Seo, SB
    Chakravarti, D
    Szyf, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) : 25026 - 25031